TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10904122
Drug: TSD +
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TSD + Light Therapy
Study: 1735865
Drug: Heparin surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface modified intraocular lenses
Study: 1735865
Drug: Control intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control intraocular lenses (PMMA without heparin)
Study: 31205265
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme (thrice weekly, supervised exercise on a static bike for six weeks)
Study: 22985567
Drug: Super Lizer
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Lizer group (daily linearly polarized near-infrared irradiation)
Study: 22985567
Drug: S+P group
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: S+P group (daily Super Lizer and aerothermotherapy)
Study: 22985567
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug therapy and shoulder exercise)
Study: 18353503
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron (0.15 mg/kg; maximum 4 mg)
Study: 9696240
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication or other types of analgesics
Study: 2672485
Drug: Doxapram (variable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (variable rate infusion)
Study: 26860434
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group), duration 6 weeks.
Study: 24692480
Drug: Early goal‐directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal‐directed fluid therapy (EGDT) guided by preload volume and cardiac output monitored by transpulmonary thermodilution
Study: 24692480
Drug: Standard less‐invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard less‐invasive hemodynamic therapy guided by fluid balance or central venous pressure
Study: 23155313
Drug: Intraderal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderal route (ID) with recombinant hepatitis B vaccine (Engerix B) 2 μg
Study: 23155313
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route (IM) with recombinant hepatitis B vaccine (Engerix B) 10 μg
Study: 19330600
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with telmisartan 40 mg/day and hydrochlorothiazide (HCTZ) 12.5 mg/day (T + H, n = 32)
Study: 19330600
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in current drug regimen (CTL, n = 32)
Study: 17890789
Drug: Mild diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild diuretic treatment in addition to standard treatment for acute COPD exacerbation (group 1A)
Study: 17890789
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for acute COPD exacerbation (group 1B)
Study: 8200888
Drug: Electrical capacitive
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical capacitive coupling treatment
Study: 12683477
Drug: Abbreviated cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated cognitive‐behavioral insomnia therapy (ACBT)
Study: 8875723
Drug: 6-month chemotherapy
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month chemotherapy (streptomycin, rifampicin, isoniazid)
Study: 8875723
Drug: 9-month chemotherapy
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month chemotherapy (streptomycin, rifampicin, isoniazid)
Study: 8875723
Drug: 18-month chemotherapy
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-month chemotherapy (streptomycin, sodium para-aminosalicylic acid, isoniazid)
Study: 8875723
Drug: All chemotherapy
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All chemotherapy regimens (6-month, 9-month, 18-month)
Study: 7933184
Drug: Maximal electrical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal electrical sphincter stimulation (30 minutes twice daily for 12 days)
Study: 2853406
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and placebo (combined control group)
Study: 28043937
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg, once daily)
Study: 22130488
Drug: Enoxaparin followed
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin followed by idrabiotaparinux (5-10 days' enoxaparin 1.0 mg/kg twice daily followed by subcutaneous idrabiotaparinux starting dose 3.0 mg)
Study: 22130488
Drug: Enoxaparin plus
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin plus warfarin (adjusted-dose warfarin with target INR 2.0-3.0)
Study: 18478934
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Shenqi-fuzheng injection
Study: 16335682
Drug: EP treatment
Normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP treatment with 2mg of estradiol (E2) for 5 years
Study: 16335682
Drug: EP treatment
Normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP treatment with 2mg of estradiol (E2) started before age 15
Study: 16335682
Drug: EP treatment
Normalized name: Clearasil Rapid Rescue Deep Treatment 2% Topical Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP treatment with 2mg of estradiol (E2) started after age 20
Study: 9685472
Drug: Vaccine Information
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Information Statement (VIS) only
Study: 8062601
Drug: 50/50 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 insulin mixture
Study: 8062601
Drug: 70/30 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70/30 insulin mixture
Study: 30054099
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) group (2-visit treatment)
Study: 30054099
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide group (2-visit treatment)
Study: 29146633
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of antibiotics (including an option for complete outpatient therapy)
Study: 29146633
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of antibiotics
Study: 26396054
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of daily walnut intake for 4 weeks
Study: 26396054
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of daily walnut intake for 4 weeks
Study: 18471953
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (Laser)
Study: 17071205
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (3 g/d) and vitamin D (1 g/d) for 2 weeks
Study: 11095326
Drug: Alendronate 40
Normalized name: ALENDRONATE 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 40 mg/day (N = 90)
Study: 11095326
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg/day (N = 89)
Study: 11095326
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin 650 mg q.i.d. for the last 7 days (N = 20)
Study: 9366932
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus followed by 2 micrograms/kg/min infusion for 24 hours, then 1 microgram/kg/min for 48 hours)
Study: 1564126
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg daily for 28 days
Study: 1564126
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg daily
Study: 27136251
Drug: Pittsburgh Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pittsburgh Sleep Quality Index (PSQI) administered at baseline, 2, 6, and 12 months after transplant; 12-month PSQI categorized good versus poor sleepers.
Study: 24931322
Drug: Vatreptacog alfa
Normalized name: Vatreptacog alfa
DrugBank: Vatreptacog alfa (DB12409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatreptacog alfa (80 μg kg(‐1), one to three doses)
Study: 24931322
Drug: rFVIIa (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (90 μg kg(‐1), one to three doses)
Study: 12803872
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ivermectin and albendazole
Study: 7019839
Drug: Theophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (250 mg fast release)
Study: 7019839
Drug: Terbutaline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (2.5 mg)
Study: 7400476
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline and Terbutaline
Study: 7019839
Drug: Theophylline or
Normalized name: theophylline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline or Terbutaline (alone or in combination)
Study: 28074556
Drug: Isavuconazole (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (therapeutic or supratherapeutic doses daily for 11 days after a 2-day loading dose)
Study: 28074556
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg q.d.)
Study: 26621254
Drug: Chemoradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy with cisplatin and 9 l of saline solution during hydration in the first, fourth, and seventh week
Study: 21135055
Drug: High-dose platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose platinum-based chemotherapy (HD-PB)
Study: 31956037
Drug: Conventional anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anthracycline-based chemotherapy
Study: 17089581
Drug: Microalbuminuria assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microalbuminuria assessment after one month of treatment
Study: 15587750
Drug: Right internal
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right internal jugular group (G-RIJV)
Study: 15587750
Drug: Left subclavian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left subclavian group (G-LSCV)
Study: 15587750
Drug: Right subclavian
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right subclavian group (G-RSCV)
Study: 15587750
Drug: Left internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left internal jugular vein group (G-LIJV)
Study: 9258415
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy (0.125 IU/kg per week for the first 4 weeks, then 0.25 IU/kg per week)
Study: 8276025
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 5-15 micrograms/kg per min
Study: 8276025
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 5-15 micrograms/kg per min
Study: 3106656
Drug: Glyburide, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide, 20 mg/d (plus insulin)
Study: 3106656
Drug: Placebo (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus insulin)
Study: 30553231
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (500 mL/d)
Study: 28986984
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cor a 1 and Cor a 9
Study: 27733375
Drug: Three preoperative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three preoperative cycles of epirubicin 120 mg/m2 and ifosfamide 9 g/m2 (Arm A)
Study: 27733375
Drug: Five cycles
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five cycles of adjuvant chemotherapy (Arm B)
Study: 27733375
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of chemotherapy (Arm A)
Study: 27733375
Drug: Five cycles
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five cycles of chemotherapy (Arm B)
Study: 2574045
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to therapy
Study: 15749318
Drug: Other preparations
Normalized name: other preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other preparations applied for 1 min
Study: 15749318
Drug: Sterillium applied
Normalized name: Trillium erectum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterillium applied for 1.5 min (2 x 3 mL)
Study: 11867404
Drug: Epinephrine‐15 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine‐15 group (3 mL of 1.5% lidocaine containing 15 microg epinephrine)
Study: 11867404
Drug: Epinephrine‐10 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine‐10 group (2 mL of test dose)
Study: 11867404
Drug: Epinephrine‐5 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine‐5 group (1 mL of test dose)
Study: 11049908
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (3 mL of normal saline IV)
Study: 7781586
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg at a daily dosage of 100 mg t.i.d. (25 mg - 25 mg - 50 mg)
Study: 7781586
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg at a daily dosage of 4 mg t.i.d. (1 mg - 1 mg - 2 mg)
Study: 28550023
Drug: CC 100
Normalized name: HYDROCORTISONE NA SUCC 1000MG/VI INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC 100 mg
Study: 23363494
Drug: Custodiol HTK
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custodiol HTK solution
Study: 19748405
Drug: Local manipulative
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local manipulative therapy combined with exercise and soft tissue treatment
Study: 19748405
Drug: Full kinetic
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full kinetic chain manipulative therapy combined with exercise and soft tissue treatment
Study: 15627856
Drug: Brief Dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Dynamic Therapy (BDT)
Study: 12118806
Drug: Slow load
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow load amiodarone (7 g oral amiodarone more than 10 days starting 5 days before OHS; n = 56)
Study: 12118806
Drug: Fast load
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast load amiodarone (6 g oral amiodarone more than 6 days starting 1 day before OHS; n = 64)
Study: 10403145
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day for first 6 weeks, adjusted to 20-50 mg/day thereafter)
Study: 10403145
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day for first 6 weeks, adjusted to 20-80 mg/day thereafter)
Study: 2129373
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of IV beta blocker (metoprolol)
Study: 2129373
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of beta blocker (starting on Day 6)
Study: 7404301
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline and 2 g tinidazole (single preoperative dose)
Study: 7404301
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg gentamicin and 600 mg clindamycin (three doses with eight hour intervals, starting one hour preoperatively)
Study: 26051455
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of misoprostol
Study: 23812769
Drug: Single-dose intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intraoperative radiation therapy (IORT)
Study: 23812769
Drug: 6-week whole-breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week whole-breast external-beam radiation therapy (WB-EBRT)
Study: 16707395
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg daily for 2 weeks
Study: 2284219
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg twice daily for 14 days
Study: 2284219
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg, indomethacin 50 mg, or placebo twice daily for 29 days
Study: 2284219
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg twice daily for 29 days
Study: 2284219
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 29 days
Study: 7457801
Drug: Controlled mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled mechanical ventilation, relaxation, intravenous anaesthesia, at least 1 1 fluid replacement, careful monitoring
Study: 26970404
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (single-dose)
Study: 26677665
Drug: SGRS Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGRS Chinese herbs as adjuvant therapy
Study: 23013325
Drug: Monthly alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly alcohol consumption by mothers
Study: 22198102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 100 mg aspirin and 200 mg cilostazol
Study: 18204334
Drug: Aripiprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2 mg/d, titrated to a maximum of 30 mg/d at day 28)
Study: 12562459
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (90 mg)
Study: 12562459
Drug: Caraway oil
Normalized name: Caraway Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caraway oil (50 mg)
Study: 12562459
Drug: n-butylscopolamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-butylscopolamine (10 mg)
Study: 6324586
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (20 cc/kg weekly doses before and after transplantation)
Study: 25533447
Drug: Palonosetron (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.75 mg on day 1)
Study: 25533447
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg twice daily on days 1 through 5)
Study: 25533447
Drug: Combination antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiemetic therapy (5‐HT3 receptor antagonists, NK‐1RAs, and dexamethasone)
Study: 20689518
Drug: Subcutaneous rEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rEPO at 250 units kg(‐1) per dose, three times weekly for 6 weeks
Study: 20689518
Drug: Subcutaneous rEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rEPO at 750 units kg(‐1) per dose, once weekly for 6 weeks
Study: 19004650
Drug: Tonic rectal
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic rectal electrical stimulation
Study: 19004650
Drug: Tonic rectal
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic rectal distension stimulation
Study: 16933087
Drug: High fidelity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fidelity Integrated Dual Disorders Treatment program
Study: 11359482
Drug: Tooth-implant connected
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-implant connected prostheses
Study: 11359482
Drug: Freestanding implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freestanding implant-supported prostheses
Study: 11359482
Drug: Rigid tooth-implant
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigid tooth-implant connected prostheses
Study: 3436154
Drug: Isoxicam (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam (400 mg single dose)
Study: 3436154
Drug: Isoxicam (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam (repeated dosing)
Study: 21733727
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg every 8 h (MDD)
Study: 21733727
Drug: Amikacin 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 22.5 mg/kg as a single dose (ODD)
Study: 15297066
Drug: Fluarix (1/10th
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix (1/10th dose)
Study: 15297066
Drug: Fluarix (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix (full dose)
Study: 9579717
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg once daily for 8-10 days